Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (NASDAQ: BIVI) generates news primarily through its clinical development programs in neurological and neurodegenerative disorders and advanced liver disease. Company announcements frequently highlight progress with its lead candidate bezisterim (NE3107) in Alzheimer’s disease, Parkinson’s disease and long COVID, as well as developments in its BIV201 program for complications of advanced liver cirrhosis.
Recent news releases have described milestones in the SUNRISE-PD Phase 2 trial in early Parkinson’s disease, including the use of a hybrid, decentralized design that allows participants to complete visits at home or in clinics, and the completion of enrollment in that study. BioVie also issues updates on scientific presentations at international conferences, where it has discussed bezisterim’s potential effects on biological aging markers, DNA methylation patterns, inflammatory gene expression, and metabolic and inflammatory biomarkers in Alzheimer’s disease.
In long COVID, BioVie’s news flow includes coverage of the ADDRESS-LC Phase 2 trial, which is enrolling adults with fatigue and cognitive impairment associated with long COVID and is fully funded by a U.S. Department of Defense grant. Press releases describe the trial’s enrichment strategy, objective cognitive endpoints, and the rationale for targeting neuroinflammation and insulin resistance in this condition.
BioVie also reports on capital markets and corporate events, such as underwritten public offerings of units consisting of common stock (or pre-funded warrants) and warrants, the listing of its warrants under the symbol BIVIW, and investor webinars featuring management discussing clinical data and program updates. Regulatory and governance news, including reverse stock split implementation, proxy statements, and board appointments, is disclosed through SEC filings and related communications.
Investors and observers following BIVI news can expect updates on clinical trial enrollment and topline data timing, scientific presentations, financing transactions, and corporate governance actions, all of which are documented in the company’s press releases and regulatory filings.
BioVie announced two poster presentations at the ATMRD Congress in Washington, D.C., from June 21-25, 2024. The presentations will focus on the Phase 2 trial protocol for bezisterim (NE3107) in early Parkinson’s patients and its impact on motor and non-motor symptoms, specifically for those not yet treated with carbidopa/levodopa. The first poster will be displayed on June 22 from 5-5:30 p.m. EDT, outlining the study protocol. Another poster will be shown the same day from 4:20-4:50 p.m. EDT, featuring data on bezisterim’s effects when used alongside carbidopa/levodopa.
BioVie (NASDAQ: BIVI), a clinical-stage company focused on neurological, neurodegenerative, and liver diseases, will host a live investor webinar on June 26, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Cuong Do, discussing the company's clinical pipeline, including bezisterim (formerly NE3107). Bezisterim has shown promising results in reducing inflammation, insulin resistance, and improving symptoms in Parkinson's and Alzheimer's diseases. Strategic priorities include a Phase 2b trial for Parkinson's in Fall 2024, a Phase 3 trial for Alzheimer's in mid-2025, and ongoing partnering discussions.
BioVie announced the formation of an Advisory Board to guide the Phase 2b trial of bezisterim for long COVID, funded by a $499,200 award from the U.S. Department of Defense. The board includes experts from UCSF and Northwestern Feinberg School of Medicine, and industry veterans.
The trial aims to evaluate bezisterim, an anti-inflammatory and insulin-sensitizer, for reducing neurocognitive symptoms in long COVID patients. The trial, involving 200 patients, will assess safety and efficacy over three months.
The Department of Defense may provide an additional $12.6 million upon successful completion of the planning phase and meeting specific milestones.
BioVie announced promising results from a Phase 2a trial of their drug bezisterim for Parkinson's disease. Data presented at the XXIX World Congress on Parkinson's Disease and Related Disorders showed that patients treated with bezisterim in combination with levodopa/carbidopa experienced significant improvements in both motor and non-motor symptoms compared to placebo. Notably, bezisterim-treated patients saw a -2.8 point improvement on the motor section of the MDS-UPDRS scale. For patients under 70, the improvement was -4.7 points. Additionally, bezisterim-treated patients showed significant gains in sleep/fatigue and leg restlessness symptoms. These findings suggest bezisterim's potential as an adjunct therapy, warranting further investigation in late-phase trials.
BioVie Inc. (NASDAQ: BIVI) secured up to $13.1 million from the U.S. Department of Defense for a Phase 2b clinical trial evaluating bezisterim (NE3107) in treating long COVID symptoms. Long COVID is a condition where symptoms persist post SARS-CoV-2 infection. The trial aims to assess the drug's effectiveness in reducing neurological symptoms associated with long COVID. Bezisterim, an anti-inflammatory and insulin-sensitizer capable of permeating the blood-brain barrier, targets inflammation, a key factor in long COVID. The trial is expected to begin in early 2025 and includes 200 patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.